Compugen Posts Zero Q1 Revenue Amid R&D Spending Slide and Flat Loss | GenomeWeb
NEW YORK (GenomeWeb News) — Compugen today reported it earned no revenue for the first quarter as R&D spending decreased 7 percent and net loss remained flat.
 
The company reported $200,000 in revenue for the first quarter last year.
 
Compugen said R&D spending in the quarter dipped to $2.5 million from $2.7 million year over year.
 
Net loss for the quarter increased slightly to $3.11 million from $3.09 million last year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.